<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03163602</url>
  </required_header>
  <id_info>
    <org_study_id>15-116</org_study_id>
    <nct_id>NCT03163602</nct_id>
  </id_info>
  <brief_title>Surgical Treatment of Peri-implantitis</brief_title>
  <acronym>STP</acronym>
  <official_title>Surgical Treatment of Peri-implantitis. A Randomised Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Western Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Osteology Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Western Australia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized controlled study is to evaluate the outcome of surgical treatment
      of peri-implantitis with and without the use of a bone substitute graft covered by a collagen
      membrane. There will be a follow up period of 12 months. Outcome measures will include
      assessments of inflammation, probing depth, recession, radiological parameters and PROMs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this randomized controlled study is to evaluate the possible benefit of a
      regenerative treatment protocol (placing a bone substitute covered by a bioresorbable
      collagen membrane) compared to surgical treatment alone, for peri-implantitis therapy.

      The hypothesis is that there will be a greater number of patients with successful treatment
      of peri-implantitis following the use of a bone substitute/collagen membrane compared to
      surgical peri-implantitis therapy without the bone substitute/collagen membrane.

      The project will be conducted as a two-armed randomized controlled clinical trial of 1-year
      duration. Forty systemically healthy patients with ≥1 implant diagnosed with peri-implantitis
      requiring surgical therapy will be enrolled.

      Baseline measurements will be performed after non-surgical therapy (removal supramucosal
      biofilm/calculus, oral hygiene instruction and correction of prosthetic factors) and
      treatment of periodontitis.

      Baseline measurements will include probing depth, position of mucosal margin, presence of
      plaque, presence of bleeding and/or suppuration on probing, PROMs and radiographs.
      Measurements will be recorded at 4 sites per implant.

      Following the baseline measurements participants will be randomly assigned to either Control
      Group (Group 1): access flap and implant cleaning or Test Group (Group 2): access flap,
      implant cleaning and addition of a bone substitute material covered by a collagen membrane.

      Participants in both treatment groups will be prescribed systemic antimicrobials (Amoxicillin
      500 mg tds and Metronidazole 400 mg tds) for 7 days starting from the day of surgery.

      In addition an antibacterial mouthrinse (chlorhexidine digluconate 0.2%) will be prescribed
      for a period of 4 weeks following surgery.

      Participants will be asked to attend follow-up visits for review of healing (week 1 and 4)
      and maintenance care (3, 6, 9, and 12 months).

      Clinical examinations will be performed by a calibrated blinded examiner at 6 and 12 months
      after therapy. Clinical measurements will be taken using a periodontal probe at 4 sites per
      implant to record presence of plaque, bleeding, probing depth and recession of the soft
      tissue.

      PROMS will be assessed at 1 week, 4 weeks and at 6 and 12 months. Radiographic assessments
      Intra-oral radiographs and cone beam CT scan will be obtained prior to surgery and at 12
      months. Oral-maxillofacial radiologists will. perform the radiographic analysis and will be
      blinded to the treatment procedure.

      Primary outcome variables include (1) resolution of peri-implantitis (probing depth reduction
      and absence of BoP, suppuration) (2) recurrence of disease (BoP, suppuration and increase in
      PPD and progression of bone loss.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>resolution of peri-implantitis</measure>
    <time_frame>12 months</time_frame>
    <description>no bleeding or suppuration on probing, no further bone loss, reduction in probing depth</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>probing depth change</measure>
    <time_frame>12 months</time_frame>
    <description>mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radiographic bone level change</measure>
    <time_frame>12 months</time_frame>
    <description>mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in peri-implant soft tissue level</measure>
    <time_frame>12 months</time_frame>
    <description>mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient reported outcomes</measure>
    <time_frame>1, 6, 12 months</time_frame>
    <description>VAS scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Peri-Implantitis</condition>
  <arm_group>
    <arm_group_label>Control Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Access flap, implant surface decontamination (saline), systemic antibiotics (amoxicillin 500 mg and metronidazole 400 g, 3 x day for 7 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Access flap, implant surface debridement, systemic antibiotics (amoxicillin 500 mg, metronidazole 400 g, 3 x day for 7 days), bovine bone substitute material (BioOss®) and collagen membrane (BioGide®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>Access flap and debridement</description>
    <arm_group_label>Control Group 1</arm_group_label>
    <other_name>Access flap and debridement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Test group</intervention_name>
    <description>Regenerative treatment</description>
    <arm_group_label>Test Group 2</arm_group_label>
    <other_name>BioOss®, BioGide® collagen membrane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Presence of ≥ 1 implant with a probing depth (PD) ≥ 5 mm with bleeding and/or suppuration
        (SUP) on probing, and peri-implant bone loss ≥ 3mm with an intraosseous defect component

        Exclusion Criteria:

          -  Smokers &gt; 10 cigarettes per day

          -  Patients with uncontrolled diabetes mellitus

          -  Pregnant or lactating women (self reported)

          -  Patients with a systemic illness that preclude them from oral surgery

          -  Patients with an allergy to amoxicillin or metronidazole or chlorhexidine.

          -  Patients requiring antibiotic prophylaxis and Patients who have taken antibiotics in
             the past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Heitz-Mayfield, OdontDr</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Western Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Heitz-Mayfield, Odont Dr</last_name>
    <phone>(+61 0861101686)</phone>
    <email>heitz.mayfield@iinet.net.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fritz Heitz, MDsc</last_name>
    <phone>(+61 0861101686)</phone>
    <email>fritz.heitz@iinet.net.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Western Australia</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Heitz-Mayfield, Odont Dr</last_name>
      <phone>0861101686</phone>
      <email>heitz.mayfield@iinet.net.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Esposito M, Grusovin MG, Worthington HV. Treatment of peri-implantitis: what interventions are effective? A Cochrane systematic review. Eur J Oral Implantol. 2012;5 Suppl:S21-41. Review.</citation>
    <PMID>22834392</PMID>
  </reference>
  <reference>
    <citation>Heitz-Mayfield LJ, Mombelli A. The therapy of peri-implantitis: a systematic review. Int J Oral Maxillofac Implants. 2014;29 Suppl:325-45. doi: 10.11607/jomi.2014suppl.g5.3. Review.</citation>
    <PMID>24660207</PMID>
  </reference>
  <reference>
    <citation>Carcuac O, Derks J, Charalampakis G, Abrahamsson I, Wennström J, Berglundh T. Adjunctive Systemic and Local Antimicrobial Therapy in the Surgical Treatment of Peri-implantitis: A Randomized Controlled Clinical Trial. J Dent Res. 2016 Jan;95(1):50-7. doi: 10.1177/0022034515601961. Epub 2015 Aug 18.</citation>
    <PMID>26285807</PMID>
  </reference>
  <reference>
    <citation>Heitz-Mayfield LJA, Salvi GE, Mombelli A, Loup PJ, Heitz F, Kruger E, Lang NP. Supportive peri-implant therapy following anti-infective surgical peri-implantitis treatment: 5-year survival and success. Clin Oral Implants Res. 2018 Jan;29(1):1-6. doi: 10.1111/clr.12910. Epub 2016 Jun 23.</citation>
    <PMID>27335316</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2017</study_first_submitted>
  <study_first_submitted_qc>May 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Western Australia</investigator_affiliation>
    <investigator_full_name>Lisa Heitz-Mayfield</investigator_full_name>
    <investigator_title>Adj Professor</investigator_title>
  </responsible_party>
  <keyword>Peri-Implantitis</keyword>
  <keyword>Infection</keyword>
  <keyword>Bone substitutes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peri-Implantitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

